Cel Type 2 diabetes (T2D) is one of the leading causes of death through its deleterious effects on cardiovascular disease (CVD). The complications of T2D can be reduced through early and appropriate preventive and therapeutic interventions. Several studies suggest that epigenetics may play a key role in the pathogenesis of these diseases. However, additional studies are needed to improve primary prevention and treatment of T2D and vascular complications. Our overall objective is to identify novel epigenetic biomarkers of clinical relevance that predict, monitor progression and forecast response to treatment of T2D and CVD. First we aim to identify clinically useful epigenetic biomarkers (DNA methylation will be analysed genome-wide) that can predict the glycaemic response to metformin treatment and future risk of CVD in newly diagnosed T2D patients recruited from ANDIS cohort. Second, the most efficient epigenetic biomarkers identified will be validated in T2D patients from ANDIS using pyrosequencing. Third, we aim to make combined predictive risk scores with our novel epigenetic biomarkers, genetic and clinical risk factors to assess risk for CVD. Finally, we will test functional characterization of the validated epigenetic biomarkers in target tissues from T2D patients, and in vitro follow-up studies will be developed. This project represents an outstanding opportunity for personalized treatment for T2D, proposing for the first time pharmacoepigenetics in this field, and also for the development of a panel of high-quality epigenetic biomarkers together with combined risk scores, aiming to give a new reliable clinical tool for early prevention of CVD in T2D patients. Notably, epigenetic modifications can be manipulated more readily than genomic mutations, and thereby has much of potential for pharmacological applications. In summary, the findings of robust epigenetic biomarkers will optimize the therapeutics of T2D and the preventive care of vascular complications. Dziedzina nauki medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsmedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health scienceshealth sciencespersonalized medicinenatural sciencesbiological sciencesgeneticsepigenetics Program(-y) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Temat(-y) MSCA-IF-2015-EF - Marie Skłodowska-Curie Individual Fellowships (IF-EF) Zaproszenie do składania wniosków H2020-MSCA-IF-2015 Zobacz inne projekty w ramach tego zaproszenia System finansowania MSCA-IF-EF-ST - Standard EF Koordynator LUNDS UNIVERSITET Wkład UE netto € 173 857,20 Adres Paradisgatan 5c 22100 Lund Szwecja Zobacz na mapie Region Södra Sverige Sydsverige Skåne län Rodzaj działalności Higher or Secondary Education Establishments Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 173 857,20
